Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.93
-0.02 (-0.18%)
Aug 21, 2026, 11:35 AM EDT - Market open
Keros Therapeutics Employees
Keros Therapeutics had 92 employees as of June 30, 2026. The number of employees decreased by 56 or -37.84% compared to the same quarter last year.
Employees
92
Change
-56
Growth
-37.84%
Revenue / Employee
$163,196
Profits / Employee
-$903,902
Market Cap
216.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 92 | -56 | -37.84% |
| Mar 31, 2026 | 87 | -76 | -46.63% |
| Dec 31, 2025 | 78 | -91 | -53.85% |
| Sep 30, 2025 | 82 | -78 | -48.75% |
| Jun 30, 2025 | 148 | -1 | -0.67% |
| Mar 31, 2025 | 163 | 22 | 15.60% |
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Sep 30, 2024 | 160 | 31 | 24.03% |
| Jun 30, 2024 | 149 | 28 | 23.14% |
| Mar 31, 2024 | 141 | 34 | 31.78% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Sep 30, 2023 | 129 | 25 | 24.04% |
| Jun 30, 2023 | 121 | 24 | 24.74% |
| Mar 31, 2023 | 107 | 32 | 42.67% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Sep 30, 2022 | 104 | 59 | 131.11% |
| Jun 30, 2022 | 97 | 53 | 120.45% |
| Mar 31, 2022 | 75 | 37 | 97.37% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Immunic | 100 |
| Compugen | 75 |
| Acumen Pharmaceuticals | 61 |
| PepGen | 57 |
| NovaBridge Biosciences | 30 |
KROS News
- 10 days ago - Keros Therapeutics price target lowered to $17 from $20 at BofA - TheFly
- 17 days ago - Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo - TheFly
- 17 days ago - Keros Therapeutics price target lowered to $23 from $30 at Leerink - TheFly
- 17 days ago - Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24) - TheFly
- 17 days ago - Keros Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 17 days ago - Keros Therapeutics Earnings release: Q2 2026 - Filings
- 17 days ago - Keros Therapeutics Quarterly report: Q2 2026 - Filings
- 21 days ago - Keros Therapeutics to receive $20M elritercept milestone payment from Takeda - TheFly